Biography and Research Information
OverviewAI-generated summary
Adrianne Parkey's research focuses on pediatric health, with recent publications examining treatments for pediatric-onset multiple sclerosis and a case report on reversible pulmonary arterial hypertension in a child. Parkey is an Assistant Professor at the University of Arkansas for Medical Sciences. Her work includes collaborations with researchers such as Debopam Samanta, Raghu Ramakrishnaiah, Praveen Kumar Ramani, and Hannah Lewis, all at the University of Arkansas for Medical Sciences, with whom she has co-authored publications.
Metrics
- Publications: 2
Positions
-
Assistant Professor 2021–presentUniversity of Arkansas for Medical Sciences Pediatric Neurology ORCID
Selected Publications
-
First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort (2026)
-
Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report (2026)
Collaboration Network
Top Collaborators
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- Reversible Pulmonary Arterial Hypertension Due to Fenfluramine in a Young Child: A Case Report
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
- First-Line Rituximab in Pediatric-Onset Multiple Sclerosis: Clinical and MRI Outcomes in a Retrospective Cohort
Similar Researchers
Based on overlapping research topics